Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 13, 2017 - Issue 3
Submit an article Journal homepage
1,323
Views
10
CrossRef citations to date
0
Altmetric
Research Papers

The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model

Ashleigh A. McGirrDalla Lana School of Public Health, University of Toronto, Toronto, ON, CanadaCorrespondence[email protected]
,
Kevin L. SchwartzDivision of Infectious Disease, The Hospital for Sick Children, Toronto, ON, Canada;Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada
,
Upton AllenDivision of Infectious Disease, The Hospital for Sick Children, Toronto, ON, Canada;Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada
,
Melinda SolomonDivision of Respirology, The Hospital for Sick Children, Toronto, ON, Canada
&
Beate SanderInstitute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada;Public Health Ontario, Toronto, ON, Canada;Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
Pages 599-606 | Received 30 Jun 2016, Accepted 08 Sep 2016, Published online: 17 May 2017

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Omendra Narayan, Anthony Bentley, Katie Mowbray, Monika Hermansson, Dominic Pivonka, Eric Ngonga Kemadjou & Jonathan Belsey. (2020) Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK. Journal of Medical Economics 23:12, pages 1640-1652.
Read now

Articles from other publishers (9)

Affan Shoukat, Elaheh Abdollahi, Alison P. Galvani, Scott A. Halperin, Joanne M. Langley & Seyed M. Moghadas. (2023) Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study. The Lancet Regional Health - Americas 28, pages 100629.
Crossref
Deborah A. Marshall, Brittany Gerber, Diane L. Lorenzetti, Karen V. MacDonald, Riley Jewel Bohach & Gillian R. Currie. (2023) Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies. PharmacoEconomics 41:12, pages 1563-1588.
Crossref
Nisha Thampi, Braden D. Knight, Kednapa Thavorn, Richard J. Webster, Krista Lanctot, Steven Hawken & J. Dayre McNally. (2021) Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study. CMAJ Open 9:4, pages E948-E956.
Crossref
Bishal Mohindru, David Turner, Tracey Sach, Diana Bilton, Siobhan Carr, Olga Archangelidi, Arjun Bhadhuri & Jennifer A. Whitty. (2019) Health State Utility Data in Cystic Fibrosis: A Systematic Review. PharmacoEconomics - Open 4:1, pages 13-25.
Crossref
Bishal Mohindru, David Turner, Tracey Sach, Diana Bilton, Siobhan Carr, Olga Archangelidi, Arjun Bhadhuri & Jennifer A. Whitty. (2019) Health economic modelling in Cystic Fibrosis: A systematic review. Journal of Cystic Fibrosis 18:4, pages 452-460.
Crossref
Stephen MacAmanda SumnerSamuel Duchesne-BelangerRobert StirlingMatthew TunisBeate Sander. (2019) Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review. Pediatrics 143:5.
Crossref
Emma Warren, Kristen Morgan, Toby J. Toward, Matthias Schwenkglenks & Joanna Leadbetter. (2019) Cost Effectiveness of Inhaled Mannitol (Bronchitol®) in Patients with Cystic Fibrosis. PharmacoEconomics 37:3, pages 435-446.
Crossref
Megan R. Kiedrowski & Jennifer M. Bomberger. (2018) Viral-Bacterial Co-infections in the Cystic Fibrosis Respiratory Tract. Frontiers in Immunology 9.
Crossref
Kok Pim Kua & Shaun Wen Huey Lee. (2017) Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37:6, pages 755-769.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.